SCHEMBL3569849

SCHEMBL3569849

COc1ccc(-c2cc(CC(=O)O)cc(OCc3ccccc3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.56
FFAR1 O14842 7/20 0.55
PPARG P37231 3/20 0.54
LTB4R Q15722 1/20 0.54
LTB4R2 Q9NPC1 1/20 0.54
TP53 P04637 1/20 0.50
PKM P14618 1/20 0.50
NFKB1 P19838 1/20 0.50
RAB9A P51151 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
RXRG P48443 1/20 0.49
GSTP1 P09211 1/20 0.49
ANO1 Q5XXA6 1/20 0.48
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569632 0.89 PPARG (0.62) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3566811 0.89 FFAR1 (0.59) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3575842 0.88 FFAR1 (0.55) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3578107 0.88 PPARG (0.55) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3563479 0.86 MCL1 (0.60) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL6035486 0.86 LTB4R (0.61) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3576743 0.86 MRGPRX4 (0.54) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3572558 0.86 PPARD (0.53) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3570631 0.84 PPARD (0.57) PPARDFFAR1PPARGLTB4RLTB4R2
SCHEMBL3574622 0.84 LTB4R (0.51) PPARDFFAR1PPARGLTB4RLTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US claimed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US claimed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP claimed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP claimed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO claimed
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US disclosed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US disclosed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP disclosed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP disclosed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof BACE1, BACE2, APP PPARD 455/4885FFAR1 233/4885PPARG 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.